Tyrosine phosphorylation of CagA could efficiently be blocked by the Src and Abl inhibitor dasatinib, and thus Src and Abl represent possible targets in the treatment of CagA-positive MALT lymphoma. This evidence concerns the gene ABL1 and MALT lymphoma.